Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phas...
Main Authors: | Sharon Del Vecchio, Robert J Ellis |
---|---|
Format: | Article |
Language: | English |
Published: |
Codon Publications
2018-10-01
|
Series: | Journal of Kidney Cancer and VHL |
Subjects: | |
Online Access: | https://jkcvhl.com/index.php/jkcvhl/article/view/109 |
Similar Items
-
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
by: Bersanelli M, et al.
Published: (2018-09-01) -
Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
by: Chun Loo Gan, et al.
Published: (2021-02-01) -
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
by: Maximilian Sieg, et al.
Published: (2020-04-01) -
Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
by: Michele Iuliani, et al.
Published: (2021-08-01) -
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
by: Grassi P, et al.
Published: (2016-07-01)